| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24c81a16466b9935d61a5cf0cf840008 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
1997-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73133cf2d64f1b9837ac7c47767270fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bad844397c5bf68cac67e1663f88e45 |
| publicationDate |
1997-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2242750-A1 |
| titleOfInvention |
Antibodies with reduced net positive charge |
| abstract |
Antibodies have been modified by chemical conjugation with agents reactive with free amino groups. Among the chemical agents used in connection with the invention are heterobifunctional reagents and biotin. The modified antibodies are also used in the diagnosis and therapy of cancer and other mammalian disease. Diagnostic uses include immunoscintigraphy. The modified antibodies may be further conjugated with labels or biologically active molecules for use in diagnosis and therapy. The modified antibodies may also be formulated into pharmaceutical compositions for these purposes. |
| priorityDate |
1996-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |